天眼查显示，成立以来，包括最新一轮融资在内，强脑科技共完成六轮融资。最早于2016年完成天使轮 和Pre-A轮融资，后又在2019年完成4亿美元A轮融资，投资方包括中国电子、光大控股、德迅资本、鼎 晖投资等机构。2025年，强脑科技先后从道氏技术和三七互娱完成3000万美元Pre-B轮以及2000万美元B 轮融资。 | 2 | 2025-10-29 | B轮 | 2000万美元 | | 三七互模制投基金 | 三七互规创投基金 | 三七互娱投资强财科 技,加强腺机提口商 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 业化与业务生态共搬 | | 3 | 2025-09-02 | Pre-BRE | 3000万美元 | - | 通氏技术 | 道氏技术 | 道氏技术:拟3000 万美元以购强脑科技 | | | | | | | | | Pre-B轮优先股 | | | | | | | 中电华大科技 | 中电华大科技 | | | | | | | | 光大控股 | 光大控股 | BrainCo亮相CES20 | | 4 | 2019-0 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is experiencing rapid development and has promising commercial prospects, with a focus on diverse technical paths and applications in the medical field [5][6][32] - The BCI technology is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages in signal quality, safety, and operational difficulty [18][20] - The core technological barriers of BCI are concentrated in the upstream of the industry chain, including hardware (electrodes, chips), surgical procedures, and signal processing [25][28] Summary by Sections 1. BCI Development and Applications - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to facilitate communication between the brain and external devices [15] - The medical application of BCI is predominant, accounting for 56% of the market in 2023, with potential in diagnosing and treating cognitive disorders, mental illnesses, and motor disabilities [33][36] 2. BCI Policy and Pricing - The National Healthcare Security Administration has established a pricing standard for BCI services, addressing the slow commercialization of BCI technology and creating a pricing framework that covers the entire service chain [40][42] 3. BCI Companies and Market Trends - Non-invasive BCI products are leading in commercialization, while invasive and semi-invasive products are still in clinical research stages [43] - Key companies in the BCI space include NeuroPace, BrainGate, Neuralink, and Paradromics, each focusing on various applications such as epilepsy treatment and motor function recovery [43]